CN87105864A - 治疗创伤的制剂 - Google Patents
治疗创伤的制剂 Download PDFInfo
- Publication number
- CN87105864A CN87105864A CN87105864.2A CN87105864A CN87105864A CN 87105864 A CN87105864 A CN 87105864A CN 87105864 A CN87105864 A CN 87105864A CN 87105864 A CN87105864 A CN 87105864A
- Authority
- CN
- China
- Prior art keywords
- preparation
- weight
- sugar
- iodophors
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 239000000654 additive Substances 0.000 claims abstract description 10
- 150000004676 glycans Chemical class 0.000 claims abstract description 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940035535 iodophors Drugs 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 13
- 239000003643 water by type Substances 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 abstract description 8
- KRVIMMAOCNANRA-UHFFFAOYSA-N iodine;pyrrolidin-2-one Chemical compound [I].O=C1CCCN1 KRVIMMAOCNANRA-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 229940064804 betadine Drugs 0.000 description 6
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229920000945 Amylopectin Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗创伤的制剂,它是由50~90%按重量计的糖、0.5~10%按重量计的吡咯烷酮碘和1~20%按重量计的水组成的。此外,还含有调节制剂到pH3.5~6的足够量的缓冲液。该制剂最好另外含有0.1~5%按重量计的能赋予制剂适当粘稠度和稳定性的附加剂,该附加剂系选自多糖或其衍生物。
Description
本发明是关于治疗受伤皮肤(为简便起见,以下简称为创伤),如烧伤、褥疮和开放性创伤的稳定的外用制剂。本发明尤其是关于含有糖和吡咯烷酮碘(聚乙烯吡咯烷酮碘复合物)作为有效成分的治疗创伤的制剂。
民间治疗烧伤和开放性创伤,通常需应用糖类(如蜂蜜和糖蜜)。已知这些糖具有抑菌作用和促进肉芽组织生长的作用。吡咯烷酮碘是世界上应用十分广泛的消毒药物。
近来报道,当颗粒状的糖与吡咯烷酮碘制剂混合,如与“Betadine”油膏剂〔Betadine为Purdue Frederick公司(美国康涅狄格州,Norwalk)的商品名〕、“Betadine”溶液剂和“Isodine Gel”〔为日本东京Meiji Seika Kaisha公司的商品名〕混合,可以得到非常好的治疗创伤的效果,并且生成的混合物可以应用于各种创伤〔R.A.Knutson等,Southern Medical Journal,74(11),1329-1335(1981);Kiyokazu Sone等,Byoin Yakugaku(Hospital Pharmacology),10(5),315~322(1984)〕。
此外,1980年11月5日日本专利申请公开号141409/1980,(部分相应于美国专利4,401,651,1983年8月30日批准)公开了由20份重量颗粒状糖、5份重量“Betadine”油膏和2份重量“Betadine”溶液组成的组合物。“Betadine”。油膏剂和溶液是由美国The Purdue Frederick公司生产和销售的吡咯烷酮制剂,但是在日本没有出售。因此,它们的详细成分对本发明者来说是未知的。
按照上述日本专利申请公开号141409/1980的配方,将购买的吡咯烷酮碘制剂分别与糖相混合,本发明人发现组合物有以下的问题:
(1)在每批购来的吡咯烷酮碘制剂中,吡咯烷酮碘的含量不一致。各批组合物产品中,糖与吡咯烷酮碘的比例不同,因此很难得到统一质量的组合物。
(2)购买的吡咯烷酮碘制剂与糖的各种混合物均十分粘稠。因此,为了混合均匀,需要特殊的设备。另外,通过简单的混合,很难生产出大量的组合物。
(3)当于室温下贮存时,各个组合物均分为二层,或者变成象淀粉糖浆一样的东西,此外,由于它们的有效成分分解而使药效降低。因此,需将组合物贮存于冷暗处。但即使按该方式贮存,有效成分在几个月内也要分解。所以该组合物需要在使用前配制。
在以上问题中,组合物需要在使用前配制是一个十分麻烦的问题。因此,问题(3)产生了这样不可避免的缺点:除了具有例如上面提到的混合器、无菌操作设备、灭菌装置等的大医院能配制上述组合物之外,其余均不能配制,病人需要用药时,必须去大医院。
本发明的目的是提供治疗创伤的制剂,通过简单操作,该制剂可以配制成均一的组合物,并能够长期稳定地贮存。
为了实现本发明的上述目的,本发明人进行了广泛的研究。结果发现,应用吡咯烷酮碘代替上述吡咯烷酮碘制剂,将吡咯烷酮碘、糖和水按预定的比例混合,并用缓冲液将所得混合物的pH调节到一定值,可以得到克服上述问题的稳定制剂。本发明人还发现,在上述稳定制剂中,加入作为附加剂的多糖或其衍生物,以赋予适当的粘稠度和稳定性,可以得到更稳定的制剂,该制剂即使长期贮存也不分层。
一方面,本发明提供了治疗创伤的制剂,该制剂包括50~90%按重量计的糖,0.5~10%按重量计的吡咯烷酮碘,1~20%按重量计的水和将该制剂调到pH3.5~6的足够量的缓冲液。
另一方面,本发明也提供了治疗创伤的制剂,该制剂包括50~90%按重量计的糖,0.5~10%按重量计的吡咯烷酮碘,1~20%按重量计的水,0.1~5%选自多糖或其衍生物的附加剂,以赋予适当的粘稠度和稳定性,以及将该制剂pH调节到3.5~6的足够量的缓冲液。
本发明的制剂很容易制备,并且长期贮存是稳定的。本发明的制剂可装在不透明的容器内应用。
从下面的说明书、权利要求书以及附图1中可以明显看出本发明的目的、特点及其优越性,附图1用图解法描述了吡咯烷酮碘水溶液的稳定性与糖以及它们的pH之间的关系。
本发明中应用的糖必须为非还原性糖。糖的实例有蔗糖、葡萄糖、右旋糖、蜜、糖蜜等。其中,特别优先选用日本药局方中规定的蔗糖和纯化蔗糖,以便得到统一质量的组合物。另一方面,可以应用日本药局方准药物成分标准中所叙述的吡咯烷酮碘。
糖的比例占整个组合物重量的50~90%(后面只以%表示),最好占60~80%。吡咯烷酮碘的比例范围为0.5%(具有抑菌作用所需最低比例)~10%。加入水的量占1~20%,最好为1~15%。
多糖或其衍生物的实例有糊精、阿拉伯树胶、支链淀粉、硫酸软骨素、甲基纤维素、羧甲基纤维素钠等,它们作为附加剂可赋予制剂适当的粘稠度和稳定性。上述多糖及其衍生物对于制剂的稳定性具有特性的作用。通常应用于相同目的的其他试剂,或者不能得到满意的效果,或者相反地给予稳定性某些不利的影响。以全部组合物为基础,最好按0.1~5%,尤其按0.1~3%的量加入上述附加剂。
除了上述基本成分以外,根据需要还可加入常用的赋形剂和吡咯烷酮碘加溶剂。加溶剂的实例有碘化钾、碘化钠和甘油等。赋形剂的实例有二元醇类(如聚乙二醇400、聚乙二醇1500、聚乙二醇4000和聚乙二醇6000、聚氧乙烯聚氧丙烯二醇和聚丙二醇);丙三醇类(如甘油和聚甘油);聚氧乙烯-硬化蓖麻油;聚氧乙烯聚氧丙烯嵌段聚合物等。
当本发明的制剂仅与上述成分相加时,它的有效成分(即糖和吡咯烷酮碘)是不稳定的。因此,调节pH是必要的。即制备由80%颗粒状糖、3%吡咯烷酮碘和17%水组成的组合物。应用0.1M磷酸-柠檬酸二钠缓冲液,将各组合物调到不同的pH值,于40℃贮存二周。用高效色谱法测定各个样品中残余糖的百分含量,而各个样品中残余吡咯烷酮碘的百分含量用滴定法测定。结果用图解法表示在图1中。由上述试验表明,pH在3.5~6的范围内,糖和吡咯烷酮碘都是稳定的。
能够使本发明制剂pH调到上述范围的缓冲液实例有乳酸盐缓冲液、柠檬酸盐缓冲液、磷酸盐缓冲液、苯二甲酸氢钾缓冲液等。
本发明制剂的生产方法没有任何特别的限制。例如,可以将吡咯烷酮碘和加溶剂溶解在缓冲液中,分别配制糖的水溶液和赋予适当粘稠度和稳定性的附加剂的水溶液,或者将糖的水溶液单独地或者与附加剂的水溶液一起同时加到上述含吡咯烷酮碘、加溶剂的缓冲液中,混合,并有选择地加入赋形剂以调节粘稠度。
一般性地叙述了本发明之后,通过参考具体的实例,可以更完全理解本发明,下述实例仅是为了举例叙述本发明,除非另有说明,否则不应将下述实例看作是对本发明的限制。
实例
通过下述实例叙述本发明。
实例1 份(按重量计)
(1)吡咯烷酮碘 3
(2)0.1M乳酸-乳酸钠缓冲液(pH5.5) 11
(3)碘化钾 0.9
(4)纯化的蔗糖 70.7
(5)1N氢氧化钠溶液 1.2
(6)聚乙二醇400 9
(7)聚乙二醇6000 2.6
(8)聚氧乙烯聚氧丙烯二醇 1
(9)甘油 0.6
将成分(1)和(3)溶解在成分(2)中,向该溶液中加入成分(5)和(4)并混合。将分别准备的成分(6)、(7)、(8)和(9)混合,并逐渐地加到前面的混合物中,使所有的成分混合成均匀的制剂。
试验1
将按实例1配制的本发明产品,普通的产品-医院配方Ⅰ(Hospital Formulation Ⅰ)〔Gekkan Yakuji(The pharmaceuticals Monthly),25(7),97(1983)〕和医院配方Ⅱ(Hospital Formulation Ⅱ)〔Gekkan Yakuji(The pharmaceuticais Monthly),25(5),129(1983)〕加热至60℃,测量它们pH值的变化和残余的有效碘及糖的百分含量。结果总结于表1~3。
医院配方Ⅰ
颗粒状糖 72.4%
Isodine Gel 21.0%
Isodine Solution 6.6%
医院配方Ⅱ
颗粒状糖 57.1%
单糖浆 17.2%
Isodine Gel 25.7%
实例2
按实例1相同的方法配制由下述成分组成的制剂。
份(按重量计)
吡咯烷酮碘 3
0.1M柠檬酸盐缓冲液(pH5.3) 11
碘化钾 0.9
纯化的蔗糖 65
1N氢氧化钠 1
聚乙二醇400 8
聚乙二醇1500 7.3
聚氧乙烯聚氧丙烯二醇 2.8
甘油 1
实例3
份(按重量计)
(1)吡咯烷酮碘 3
(2)0.05M柠檬酸盐缓冲液(pH5.3) 8.9
(3)碘化钾 0.7
(4)纯化的蔗糖 70
(5)赋予适当粘稠度和稳定性的附加剂 0.5
(6)1N氢氧化钠 0.8
(7)聚乙二醇400 14
(8)聚氧乙烯聚氧丙烯二醇 1.1
(9)甘油 1.0
将成分(1)和(3)溶于成分(2)中,再将成分(6)和(4)加入并混合。将分别准备的成分(5)、(7)、(8)和(9)混合,并逐渐地加到前面的混合物中,使所有的成分混合成均匀的制剂。
试验2
下面表4是在实例3中用不同的附加剂(5)配制的制剂,于40℃贮存3个月之后,测得的各个制剂中残余的有效碘和糖的百分含量以及所观察到的制剂的粘稠度。结果总结于表4。
实例4
份(按重量计)
(1)吡咯烷酮碘 3
(2)0.1M乳酸-乳酸钠缓冲液(pH5.5) 11.0
(3)碘化钾 0.9
(4)纯化的蔗糖 70.7
(5)支链淀粉 0.6
(6)1N氢氧化钠溶液 1.2
(7)聚乙二醇400 9
(8)聚乙二醇6000 2
(9)聚氧乙烯聚氧丙烯二醇 1
(10)甘油 0.6
将成分(1)和(3)溶于成分(2),加入成分(6)和(4)并混合,将分别准备的成分(5)、(7)、(8)、(9)和(10)的混合物逐渐地加到前面的混合物中,将所有的成分混合成均匀的制剂。
在充分地叙述了本发明之后可以看出,熟悉本专业的人员可以在本发明前述精神和内容的范围内进行许多的变化和改进。
Claims (2)
1、一种治疗创伤制剂的制备方法,它包括下列步骤:
(a)将50~90%按重量计的糖、0.5~10%按重量计的吡咯烷酮碘以及1~20%按重量计的水相混合;
(b)将产生的混合物揉合成一种均匀制剂;
(c)用一种缓冲液将该均匀制剂的pH调整至3.5~6。
2、一种治疗创伤制剂的制备方法,它包括下列步骤:
(a)将50~90%按重量计的糖、0.5~10%按重量计的吡咯烷酮碘、1~20%按重量计的水以及0.1~5%按重量计的能赋予制剂适当粘稠度和稳定性的选自多糖或其衍生物的附加剂相混合。
(b)将产生的混合物揉合成一种均匀制剂;
(c)用一种缓冲液将该均匀制剂的pH调整至3.5~6。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20631286A JPS6310731A (ja) | 1986-03-12 | 1986-09-02 | 安定な損傷皮膚修復用製剤 |
JP206312/86 | 1986-09-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN87105864A true CN87105864A (zh) | 1988-03-23 |
CN1024892C CN1024892C (zh) | 1994-06-08 |
Family
ID=16521214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN87105864A Expired - Fee Related CN1024892C (zh) | 1986-09-02 | 1987-08-28 | 治疗创伤制剂的制备方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US4844898A (zh) |
EP (1) | EP0258761B1 (zh) |
KR (1) | KR910003556B1 (zh) |
CN (1) | CN1024892C (zh) |
CA (1) | CA1287584C (zh) |
DE (1) | DE3774374D1 (zh) |
ES (1) | ES2038632T3 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026928A1 (fr) * | 2004-09-09 | 2006-03-16 | Yiming Lv | Vulneraire et procede de fabrication et d'utilisation associe |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254538A (en) * | 1989-10-04 | 1993-10-19 | Trustees Of Boston University | Method of treating periodontal disease |
WO1994006297A1 (en) * | 1992-09-22 | 1994-03-31 | Arda Technologies, Co. | Antimicrobial composition and method of preparation |
GB2274988A (en) * | 1993-02-10 | 1994-08-17 | Mcconn Stern Rita | Iodine containing wound-healing preparations |
US5879717A (en) * | 1993-02-10 | 1999-03-09 | Rita McConn-Stern | Wound healing compositions containing iodine and sucrose |
DE4414254A1 (de) * | 1994-04-23 | 1995-10-26 | Basf Ag | Iodophor aus Poly-N-vinyllactam und Dextrin |
JP3583166B2 (ja) * | 1994-06-27 | 2004-10-27 | 興和株式会社 | 損傷皮膚修復用粉末製剤 |
US5618841A (en) * | 1994-07-06 | 1997-04-08 | Kross; Robert | Composition of iodophor teat dip for the prevention of mastitis and a process for using the same |
DE19527714A1 (de) * | 1995-07-31 | 1997-02-06 | Basf Ag | Zubereitungen, enthaltend ein Iodophor aus Poly-N-vinyllactam und Dextrin und Verwendung solcher Zubereitungen |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US6113950A (en) * | 1996-10-07 | 2000-09-05 | E. I. Du Pont De Nemours And Company | Process for coating biological pesticides and compositions therefrom |
WO2000050095A1 (en) | 1999-02-26 | 2000-08-31 | Warner-Lambert Company | Bioadhesive antibacterial wound healing composition |
DE19957918A1 (de) * | 1999-11-25 | 2001-06-13 | Ulrich Doht | Desinfektionsreiniger zur Reinigung und Pflege sowie Verfahren zu seiner Herstellung |
ATE260669T1 (de) | 1999-12-09 | 2004-03-15 | Apimed Medical Honey Ltd | Medizinische verbände enthaltend gelartiger honig |
US20040101507A1 (en) * | 2002-11-27 | 2004-05-27 | Janco Predovan | Skin cream |
JP4398425B2 (ja) * | 2003-03-04 | 2010-01-13 | 興和株式会社 | 損傷皮膚修復用軟膏状製剤 |
US7334538B1 (en) * | 2004-07-27 | 2008-02-26 | Aquascience Research Group, Inc. | Topical medicants for aquatic animals |
US8778369B2 (en) * | 2005-07-29 | 2014-07-15 | Delaval Holding Ab | Barrier film-forming compositions and methods of use |
WO2007048193A1 (en) * | 2005-10-26 | 2007-05-03 | Medihoney Pty Ltd | Hydrocolloid composition |
GB0619786D0 (en) | 2006-10-06 | 2006-11-15 | Inst Of Technology Sligo | An antimicrobial and immunostimulatory system |
US20100098645A1 (en) * | 2006-10-06 | 2010-04-22 | Institute Of Technology Sligo | Formulation and method for the treatment of fungal nail infections |
CA2711663C (en) * | 2007-12-31 | 2017-01-10 | 3M Innovative Properties Company | Liquid antiseptic compositions containing iodine and a sugar and/or sugar alcohol |
GB0810404D0 (en) | 2008-06-06 | 2008-07-09 | Manuka Medical Ltd | Compositions |
US20110171284A1 (en) * | 2010-01-11 | 2011-07-14 | Gilman Miles E | Povidone-iodine and sucrose wound healing dressing |
US10342891B2 (en) | 2013-09-19 | 2019-07-09 | Medline Industries, Inc. | Wound dressing containing saccharide and collagen |
US10086017B2 (en) | 2013-09-19 | 2018-10-02 | Medline Industries, Inc. | Wound dressing containing polysaccharides |
CA3195786A1 (en) * | 2020-10-15 | 2022-04-21 | Christopher MCGINLEY | Lavage systems and devices having warming component |
CN113831424A (zh) * | 2021-11-02 | 2021-12-24 | 山东华农生物制药有限公司 | 一种西地碘的制备方法 |
WO2023129596A2 (en) * | 2021-12-29 | 2023-07-06 | Dukal, Llc | Povidone iodine solution and gel, preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2826532A (en) * | 1952-04-15 | 1958-03-11 | Gen Aniline & Film Corp | Process of stabilizing polyvinyl pyrrolidone-iodine compositions |
US3911107A (en) * | 1972-12-18 | 1975-10-07 | Flow Pharma Inc | Iodine composition and dissipating solution |
US4401651A (en) * | 1979-04-18 | 1983-08-30 | Knutson Richard A | Wound-healing compositions containing povidone-iodine |
-
1987
- 1987-07-31 CA CA000543536A patent/CA1287584C/en not_active Expired - Fee Related
- 1987-08-04 US US07/081,150 patent/US4844898A/en not_active Expired - Lifetime
- 1987-08-20 KR KR1019870009077A patent/KR910003556B1/ko not_active IP Right Cessation
- 1987-08-21 DE DE8787112164T patent/DE3774374D1/de not_active Expired - Fee Related
- 1987-08-21 EP EP87112164A patent/EP0258761B1/en not_active Expired - Lifetime
- 1987-08-21 ES ES198787112164T patent/ES2038632T3/es not_active Expired - Lifetime
- 1987-08-28 CN CN87105864A patent/CN1024892C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026928A1 (fr) * | 2004-09-09 | 2006-03-16 | Yiming Lv | Vulneraire et procede de fabrication et d'utilisation associe |
Also Published As
Publication number | Publication date |
---|---|
ES2038632T3 (es) | 1993-08-01 |
KR910003556B1 (ko) | 1991-06-05 |
KR880003616A (ko) | 1988-05-28 |
CA1287584C (en) | 1991-08-13 |
EP0258761A1 (en) | 1988-03-09 |
DE3774374D1 (de) | 1991-12-12 |
US4844898A (en) | 1989-07-04 |
CN1024892C (zh) | 1994-06-08 |
EP0258761B1 (en) | 1991-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1024892C (zh) | 治疗创伤制剂的制备方法 | |
CN1158994C (zh) | 含环丙沙星和地塞米松的局部悬浮制剂 | |
DE60200416T2 (de) | Kombination von Carbidopa und Levodopa mit verzögerter Wirkstoffabgabe | |
CN1133428C (zh) | 含抗生素的局部用抗菌组合物 | |
EP0689841A1 (en) | Powder preparation for healing damaged skin | |
CN1189180C (zh) | 一种碳酸氢盐血液透析干粉组合物 | |
CN101036654A (zh) | 稳定的头孢哌酮舒巴坦药物复方制剂 | |
DE60025503T2 (de) | Pharmazeutische Zusammensetzungen, die Faropenem-Natrium und eine Diaminoacetat Verbindung zur Verbesserung der Magen-Darm-Trakt Absorption enthalten | |
US4867790A (en) | Dental composition containing an aziridine compound and method of preparation | |
KR100629326B1 (ko) | 외피용 제형 | |
JP5325779B2 (ja) | 医薬組成物 | |
JPS6310731A (ja) | 安定な損傷皮膚修復用製剤 | |
CN1137267A (zh) | 用作螯合剂的n,n′-二(2-羟基苄基)-乙二胺n,n′-二乙酸衍生物 | |
EP0112485B1 (de) | Antimykotische Mittel in Gelform zur Behandlung von Pilzinfektionen der Mundhöhle | |
CN1711095A (zh) | 损伤皮肤修复用组合物 | |
DE3819498A1 (de) | Cyclodextrinpolymerjodeinschlussverbindungen mit kontrollierter jodfreisetzung | |
CN1438887A (zh) | 水性液体制剂 | |
EP0300309A1 (de) | Autodesinfizierendes Abformmaterial | |
DE69921832T2 (de) | Pharmazeutische zusammensetzungen mit antitumoraler wirkung auf basis von carboplatin | |
CN103263399A (zh) | 一种头孢拉定胶囊剂及其制备方法 | |
JPH072646B2 (ja) | 殺菌剤組成物 | |
EP0416565B1 (de) | Verfahren zur Herstellung von Desoxycelluloseverbindungen | |
JP3910408B2 (ja) | 水性コロイド分散液 | |
US20230312763A1 (en) | Method for preparing chitin highly dispersible in aqueous phase and chitin prepared thereby | |
SU854396A1 (ru) | Состав дл лечени пародонтоза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
C19 | Lapse of patent right due to non-payment of the annual fee |